Jessica Herzig/LinkedIn
Dec 21, 2025, 13:54
Jessica Herzig on CD86 Expression Correlation with Immune Cell Activation
RPTH Journal shared on LinkedIn:
”Why do some hemophilia A patients develop inhibitors?
This study points to immune activation patterns that depend more on timing, even seasonality, than on the FVIII product itself.
Check out this fascinating study by Jessica Herzig and team here.”
Article: Season-dependent low basal CD86 expression promotes immune cell activation upon treatment with plasma-derived factor Ⅷ products
Authors: Jessica Herzig, Josselyn Azucena Arciniega Martinez, Svenja M. Küster, Eva Ringler, Stefanie Kronhart, Gerrit J. K. Praefcke, Lilija Miller, Martina Anzaghe, Zoe Waibler
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 10:27Sartaj Alam: CBC Analyzer – The Backbone of Modern Hematology Diagnostics
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC
-
May 30, 2026, 10:06Johann Morelle: Complement Inhibitors Are Reshaping Modern Nephrology
-
May 30, 2026, 09:49Flora Peyvandi: Exploring a Multidisciplinary Care Model for Hemophilia and Rare Diseases
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center